PHP35 COMPARATIVE ASSESSMENT OF POSITIVE REIMBURSEMENT LISTS AND HTA EFFECTIVENESS IN ADRIATIC REGION  by Gavrankapetanovic, I et al.
Paris Abstracts A243
2007). First, we calculated the age-adjusted hospital admission rates for adults 18      
years and older, based on the United Nations Standard Population. Second, we 
adjusted the avoidable hospitalization rates to the prevalence of corresponding condi-
tions. That was possible for three AHCs for which prevalence was documented: 
asthma, hypertension, and diabetes. To compare primary care practices, we tracked 
and followed, patients treated for pneumonia, pyelonephritis and asthma in the IMS 
DiseaseAnalyser® database based on panels of general practitioners in France and the    
UK. RESULTS: The age-adjusted and the prevalence-adjusted avoidable hospitaliza-
tion rates were simultaneously higher by 24% and 67% for the UK compared to 
France. When comparing the primary care practice in both countries for the same 
pathologies, we found that French and British GPs prescribe similarly according to            
therapeutic recommendations. The only difference we could observe was in the access 
to the primary care providers where the French health system organization makes it 
a lot easier to consult a physician and get appropriate primary care. CONCLUSIONS: 
According to the Avoidable Hospitalization indicator, the quality of primary care is 
better in France than in the UK. It allowed avoiding 18.5% of the hospitalizations for 
the 12 AHCs in 2006 which represents almost 117,000 hospitalizations. Could a         
higher quality of primary care reduce hospital expenditures?
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OBJECTIVES: For rare diseases it may be impossible to generate data from random-
ized trials to inform health policy decisions within a reasonable timeframe. Enzyme 
replacement therapies for rare diseases due to inherited metabolic enzyme deﬁciency 
provide an example of this dilemma. The Ontario Public Drug Program convened the 
Drugs for Rare Diseases Working Group (DRD WG) to develop a framework for 
assessing these drugs in a fair, transparent, and consistent way. METHODS: The DRD 
WG developed terms of reference expecting that the ideal policy product would be 
transparent, consistent, and address unique aspects of treatment of a speciﬁc rare 
condition while being adaptable to other dissimilar conditions. The perspective was 
that of a public payer addressing requests for funding generated for a speciﬁc drug, 
and included respect for the principles of “accountability for reasonableness” of 
Daniels and Sabin. Based on these principles, a consensus process was developed and 
tested by case study. RESULTS: No existing policy processes for potential adoption 
were identiﬁed, so a 7-step framework was systematically drafted: 1) Conﬁrm condi-
tion is truly “rare”; 2) Understand the disease; 3) Understand potential value of can-
didate drug; 4) Estimate clinical effectiveness of candidate drug; 5) Estimate cost 
implications and generate a funding recommendation; 6) Review evaluation with 
disease experts and stakeholders; and 7) Reassessment. The framework has been tested 
with 2 case studies: idursulfase for mucopolysaccharidosis II and alglucosidase for 
glycogen storage disease II. Estimation of clinical effectiveness was done using decision 
modeling. Funding recommendations for both drugs were generated. CONCLU-
SIONS: This policy framework attempts to address the policy challenges of funding 
drugs for rare diseases by considering available evidence in a thorough and realistic 
manner. It will inevitably require modiﬁcation with experience. This framework will 
be adapted for other drugs in future and may be of value to other policy makers.
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OBJECTIVES: Patient access schemes for novel medicines are increasingly imple-
mented in the UK, being based on linking payment to result (outcome-based) or 
capping cost per patient (ﬁnance-based). However, little is known about what schemes 
are actually being run, how useful they are perceived to be and what are the challenges 
faced. We investigated these questions. METHODS: During this qualitative survey, 
we held in depth, open-ended discussions with senior NHS/NICE representatives (n  
11), academics and health care consultants (n  6), and senior pharmaceutical industry 
representatives (n  7). The focus was on patient access schemes for new drugs imple-
mented in the UK during 2000-mid 2009. RESULTS: Of the 13 schemes identiﬁed, 
most are in oncology (n  9), and ﬁnance-based (n  8) rather than outcome-based; 
seven are included in positive NICE appraisals. Awareness and implementation of 
these schemes are highly variable, albeit less for NICE-endorsed ones. NHS respon-
dents acknowledged theoretical utility of the schemes in reducing uncertainty about 
value for money and (for local stakeholders) shifting some of budget impact risk 
towards the industry. But they saw important challenges: potentially cumbersome 
administrative burden, lack of capabilities to assess real implementation costs, and 
high uncertainty about whether relevant NHS stakeholders actually obtain the ﬁnan-
cial payback. For industry stakeholders, the schemes were essentially a means to obtain 
NICE approval following initial rejection, while preserving a high UK price (crucial 
in the context for international price referencing). A lesser consideration was the 
potential for competitive advantage through, for example, positive perceptions about 
the product and company. CONCLUSIONS: NHS and industry stakeholders generally 
see patient access schemes as beneﬁcial, at least in principle. This approach will likely 
continue for high cost drugs that would otherwise have a cost/QALY marginally over 
the accepted threshold. Adoption of more schemes will depend upon the future capa-
bility of the NHS to accurately monitor their ﬁnancial beneﬁts and implementation 
costs.
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OBJECTIVES: This study investigates the perceptions of Saudi students attending 
American universities towards a new Mandatory Cooperative Health Insurance 
Program (MCHIP) that was introduced recently in Saudi Arabia. METHODS: This 
was a cross-sectional study. Data were collected using e-survey method including all 
2210 Saudi students based on a list provided by the Saudi Cultural Mission at USA. 
Likert scale was employed to measure the students’ expectations of the MCHIP with 
respect to cost, quality, and access of health care; (1  strongly agree to 5  strongly 
disagree). Logistic regression was used to measure the effects of knowledge (knowledge 
of the MCHIP, knowledge of the American health system, and total knowledge of 
health insurance) and students’ expectations of the MCHIP regarding cost, quality 
and access. The response variable was categorized as binary; high knowledge 91), 
while low knowledge (0). Validity and reliability were done. RESULTS: Survey 
response rate was 40.6%. A total of 55.6% agree that cost will be increased while 
19.4% disagree with mean score of 2.45 (SD  1.13). A total 65.3% agree that quality 
is going to be improved, while 8.3% disagree with mean score of 2.5 (SD  0.99); 
56.3% agree that access will be improved, while 15.7% disagree with mean score 2.45 
(SD  1.04). Odds ratio of high knowledge compared to low knowledge was 2.91(P-
Value  0.001) for cost, 1.61. (P-Value  0.461) for quality, and 2.64 (P-Value  
0.203) for access. CONCLUSIONS: Majority expected MCHIP implementation will 
increase total costs, improve quality, and increase access to health care in Saudi 
Arabia. Total knowledge of health insurance had a signiﬁcant effect on students’ per-
ceptions of cost and a non-signiﬁcant effect on their perceptions of quality and access 
to health care. To promote success, the MCHIP should provide affordable and acces-
sible quality health care to the population, based on developed regulations. Awareness 
campaign should be launched.
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OBJECTIVES: Comparisons are often made between the performances of different 
countries’ health care systems. In 2000, the World Health Organisation (WHO) 
attempted to measure the performance of health systems of 191 countries and to create 
league tables of good and bad performers. However, a major assumption of the WHO 
research was that the general public had the same preferences for health care system 
attributes, no matter which country they were based. Our study aims to provide a 
pilot study to evaluate the public health preferences of citizens of the UK and Australia. 
METHODS: Eight attributes were carefully selected to convey information about a 
health care system. These included: life expectancy, infant mortality rates, waiting 
times, degree of choice, direct access to specialist, level of information provided and 
degree of funding from the public. A discrete choice experiment approach was used 
to model to preferences of the individuals. RESULTS: All characteristics affected the 
likelihood a health system would be preferred, with the exception of the additional       
tax contribution levels required to ﬁnance the system. The Australian sample was 
generally willing to forgo a greater number of years of life expectancy for gains related 
to responsiveness; whilst, the UK sample was willing to forgo a greater number of 
years for equity gains. CONCLUSIONS: The preliminary ﬁndings of this pilot study 
suggest some consistency between the health system preferences of two samples 
selected from the UK and Australia. However, they also provide some indication that    
health system exposure may affect the strength of preferences surrounding the attri-
butes that individuals consider to be important for their preferred health system.
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OBJECTIVES: The objective of this study was to compare patient access privileges to 
medicinal products through National Healthcare Reimbursement Systems in Adriatic 
region, namely Slovenia, Croatia, Bosnia and Herzegovina and Serbia. Over the past 
years, in developed countries, major advances have been made in methods and applica-
tion of health technology assessment (HTA). With the exception of Slovenia, other 
countries included in our analysis, have only recently initiated some HTA activities. 
The results of this research shall enable active engagement of national decision makers. 
METHODS: This was a simple country to country comparison of reimbursement lists. 
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Both hospital and outpatient products, as well as orphan drugs have been included in 
this analysis. All medicinal products have been assessed on the INN level, without 
differentiating original, innovative products from generics. In addition to general sta-
tistical analysis, the GDP adjusted comparison has also been performed. Subsequently 
we have also conducted more detailed analysis of the following ATC groups, known 
to be major health care cost drivers: C (cardiovascular), J (anti-infective), L (oncology), 
M (musculo-skeletal) and N (neurology, psychiatry). RESULTS: As expected, linear 
correlation between national GDP and number of reimbursed INNs have been 
observed. However, major differences in mentioned ATC groups have revealed the 
inconsistency of the current HTA activities across countries leading to sometimes 
unfair treatment possibilities for patients with different diseases which could have not 
been justiﬁed by unequal socio-economic characteristics of investigated countries. 
CONCLUSIONS: There is a strong need for the continuous education of national 
decision makers on the principles and processes of the HTA. New innovative ideas of 
ﬁnancing the health care in developing countries are urgently needed in order to ensure 
ethical standards in health care and subsequent patient access to cost effective treat-
ment, but at the same time to engage patients in investing in their personal health and 
wellbeing.
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OBJECTIVES: Since the 1990s, many articles have documented problems with US 
payers’ utilization of pharmacoeconomic studies for decision-making. By replicating 
an in-depth survey methodology, this study aimed to determine the extent to which 
US practices had changed over the past decade. METHODS: Semi-structured explor-
atory interviews were conducted in 2007 to develop a survey instrument—ﬁelded 
in 2007–08 with key formulary decision-makers at US insurers and US public payers 
in 9 pre-identiﬁed categories. The structured set of questions examined US health 
care payers’ 1) use of, and attitudes and perceptions regarding, pharmacoeconomic 
information, and 2) opinions about how pharmaceutical manufacturers present 
pharmacoeconomic information. RESULTS: Compared to 10 years ago, U.S. payers 
regard pharmacoeconomic information much more favorably, despite variation in their 
use of and attitudes toward pharmacoeconomics. Payers cluster in three groups: a 
minority who use pharmacoeconomic information frequently and rigorously; a broader 
group who examine pharmacoeconomic information informally and do rigorous analy-
sis occasionally; and a group who only review pharmacoeconomic information in 
broad terms along with other drug-related information. Across all categories, payers 
acknowledge that the quality of pharmacoeconomic studies has improved. Payers 
suggest that pharmacoeconomic studies often “answer the wrong questions”—e.g., by 
failing to identify the subset(s) of patients where the drug is most effective. Payers 
remain skeptical towards pharmacoeconomic information and studies provided/spon-
sored by industry—e.g., when they perceive companies present only favorable studies. 
Increasingly, payers separate clinical reviews from pharmacoeconomic evaluations; the 
latter may be integrated with rebating discussions. CONCLUSIONS: US payer atti-
tudes about and use of pharmacoeconomic information have improved; however, 
formal, rigorous use of cost-effectiveness analysis is not the norm. Most payers 
foresee their organizations using pharmacoeconomic evaluation slightly more and 
would welcome a neutral entity that produced pharmacoeconomic evidence—although 
some question whether even government funding could insulate it from industry and 
political inﬂuence.
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OBJECTIVES: Social Health Insurance (SHI) and National Health Service (NHS) are 
two main choices for health reform. China’s health reform during last decade is basi-
cally SHI-oriented, especially after the implementation of “Basic health Insurance 
of Urban Workers” since 1998. Theoretically speaking, a NHS system will invest 
more on preventive care than an SHI system. This research investigates the effect of 
increasing health insurance coverage on health expenditure in China, especially 
through the speciﬁc channel of preventive care. METHODS: We estimates the health 
care expenditure function with province-level panel data from 1991–2007 of China. 
The key determinates we examined are social health insurance policy implication (the 
increaseing coverage of health insurance) and the share of preventive care in health 
disbursement. Other determinants are those usually in literatures including GDP, 
doctor and beds supply, population, aging. The independent variables of interests 
are per capita health expenditure, hospitalization expenses, inspecting commission 
and medical expenses. A generalized difference-in-difference method is used to assess 
the effect of adoption of social health insurance. IV methods are used to control 
the possible endogeneity problems. RESULTS: The increasing coverage of health 
insurance is expected to contribute to health care expenditure increasing. The more 
is the spending of preventive health care, the lower the health expenditure is. More-
over, we ﬁnd social health insurance coverage has a crowding-out effect on preventive 
care expenditure. Other variables’ effects are similar to the results from literatures. 
CONCLUSIONS: “Low accessibility and high costs in health care service” is key 
problem of China’s health care system right now. The SHI oriented health reform 
is a driver of health care expenditure increasing. China has just stated of a new 
comprehensive heath care system reform. The move to SHI may be politically correct, 
but is not the best option for China. It will lead to long-term and deep crisis in the 
health sector.
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OBJECTIVES: To estimate the hospitalisation cost of ICU patients admitted to the 
TUHL in the region of Thessaly, in Greece.        METHODS: The ICU chosen is the only 
tertiary university ICU in the whole region of Thessaly accounting 27% of the total 
ICU beds. The study sample consisted of all patients (elective and emergency admis-
sions) admitted to the respective TUHL in 2006. Clinical data were derived from    
patients’ medical records on a retrospective basis whereas economic data were derived 
from the Hospital’s Financial Department. The analysis included direct costs, using 
an up-down approach under NHS perspective. The nominal and actual hospitalization 
cost per ICU patient were based on the resource utilisation and the annual hospital 
balance sheets on NHS prices in Euros. RESULTS: 312 have been admitted to the 
ICU with a total direct cost of a4,799 million suffering from stroke, COPD, cancer,  
heart, trauma, pneumonia with a mean length of stay 8.87 days. The mean cost per 
hospitalisation day in the ICU was estimated at a1,734. Mean actual cost per patient 
is estimated at a15,382 whereas social insurance funds reimburse only a1,666. Person-
nel costs are the major cost component accounting for 31% of the total cost, while 
the pharmaceuticals account for 23%, laboratory 11%, supply and oxygen 17%, 
infrastructure-hotel services expenses 18%. CONCLUSIONS: This research results in 
some meaningful conclusions for effecting changes in hospital policies for better utili-
zation of ICU resources, for optimizing patient care and incorporating economic  
assessment in decision-making.
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OBJECTIVES: The objective of the study is to obtain behaviour of the cost’s relative 
average weights of the assistance with the retrospective application of the Adjusted 
Clinical Groups (ACG’s) in 16 teams of Primary Care with an attended population 
in the clinical practice use.   METHODS: Multicentre, retrospective study based on 
electronic records of patients seeking care during 2008 in the regions of Aragon, 
Balears and Catalonia. Main measurements: universal variables (age, sex, health 
service-family practice/paediatrics) and dependent variables: episodes and total       
cost (visits, diagnostic test, referrals, drugs). The ACG case-mix System software 
(version 7.1; N  106) classiﬁed subjects into a single category for a given annual           
resource consumption. The model of cost per each patient was established differencing         
the ﬁx cost and the variable. Outlier patients were considered those surpassing 
T  Q31.5(Q3-Q1)  a1,778.6 for total cost expenditure. Log transformation of 
the dependent variable was carried out to reduce skewness of the distribution and           
make it close to normal. Explanatory power was calculated by coefﬁcients of deter-
mination (R2). Statistical software: SPSS, p  0.05. RESULTS: The total number of 
the studied patients was 227,235 (intensity of use: 75.6%), with an average 4.5         o 3.2 
episodes. The age average was of 44.1 o 23.7 years, 56.6% women (13.5% paediat-
rics). The distribution of costs was a148,657,137. The total unitary cost per patient/
year 654.2 o 851.7a (relative weights of reference). Patient’s case-mix: 57.2% of 
the study population was grouped into 10 ACG. The explanatory power of the 
ACG classiﬁcation system was 36.3% (Ln: 41.2%), p  0,001. 6.2% of patients    
were considered Outliers (N  14.066). It details the form skewness and the average         
relative weights per each category of ACG’s classiﬁcation. CONCLUSIONS: The 
ACG are an acceptable system of classiﬁcation of patients in situation of clinical 
practice use. Some ACG classiﬁcation categories should be separeted due to the high        
outliers number.
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OBJECTIVES: To study how concentrated the Finnish pharmaceutical market is in 
certain medicine groups. During the last decade the Finnish authorities have imple-
mented different acts to increase the competition in the pharmaceutical market.     
